Neurocrine/$NBIX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Neurocrine
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Ticker
$NBIX
Sector
Primary listing
Employees
1,800
Headquarters
Website
Neurocrine Metrics
BasicAdvanced
$14B
42.37
$3.39
0.28
-
Price and volume
Market cap
$14B
Beta
0.28
52-week high
$154.61
52-week low
$84.23
Average daily volume
813K
Financial strength
Current ratio
3.201
Quick ratio
2.876
Long term debt to equity
16.297
Total debt to equity
18.179
Profitability
EBITDA (TTM)
527.6
Gross margin (TTM)
63.11%
Net profit margin (TTM)
13.88%
Operating margin (TTM)
19.89%
Effective tax rate (TTM)
33.92%
Revenue per employee (TTM)
$1,390,000
Management effectiveness
Return on assets (TTM)
8.67%
Return on equity (TTM)
13.39%
Valuation
Price to earnings (TTM)
42.368
Price to revenue (TTM)
5.718
Price to book
5.28
Price to tangible book (TTM)
5.35
Price to free cash flow (TTM)
27.147
Free cash flow yield (TTM)
3.68%
Free cash flow per share (TTM)
5.292
Growth
Revenue change (TTM)
18.42%
Earnings per share change (TTM)
2.97%
3-year revenue growth (CAGR)
24.62%
10-year revenue growth (CAGR)
62.32%
3-year earnings per share growth (CAGR)
197.89%
10-year earnings per share growth (CAGR)
16.12%
What the Analysts think about Neurocrine
Analyst ratings (Buy, Hold, Sell) for Neurocrine stock.
Neurocrine Financial Performance
Revenues and expenses
Neurocrine Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Neurocrine stock?
Neurocrine (NBIX) has a market cap of $14B as of October 24, 2025.
What is the P/E ratio for Neurocrine stock?
The price to earnings (P/E) ratio for Neurocrine (NBIX) stock is 42.37 as of October 24, 2025.
Does Neurocrine stock pay dividends?
No, Neurocrine (NBIX) stock does not pay dividends to its shareholders as of October 24, 2025.
When is the next Neurocrine dividend payment date?
Neurocrine (NBIX) stock does not pay dividends to its shareholders.
What is the beta indicator for Neurocrine?
Neurocrine (NBIX) has a beta rating of 0.28. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.